Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic
| dc.rights.license | open | en_US |
| dc.contributor.author | CRACOWSKI, Jean-Luc | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOLIMARD, Mathieu | |
| dc.contributor.author | RICHARD, Vincent | |
| dc.contributor.author | ROUSTIT, Matthieu | |
| dc.contributor.author | KHOURI, Charles | |
| dc.date.accessioned | 2024-10-10T10:11:46Z | |
| dc.date.available | 2024-10-10T10:11:46Z | |
| dc.date.issued | 2024-08-01 | |
| dc.identifier.issn | 1744-764X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/202380 | |
| dc.description.abstractEn | INTRODUCTION: Drug efficacy and effectiveness are assessed respectively through clinical trials and pharmaco-epidemiological studies. However, relative and absolute benefits of drugs are distinct measures that must be considered in relation to the baseline risk of disease incidence, complication or progression. On the other hand, adverse drug reactions are independent of the basic risk but depend on the characteristics of the population treated. Given these prerequisites, how can we balance the benefits and risks of drugs? AREAS COVERED: We use the example of therapeutics evaluated during Covid to describe how assessing the benefit-risk balance of drugs is a complex process. EXPERT OPINION: Clinical trials are not designed to identify rare adverse events, underscoring the necessity for a pharmacovigilance system. Evaluating the balance between the benefits and risks of drugs is an ongoing process, demanding the simultaneous analysis of data from clinical trials, potential drug-drug interactions, pharmacovigilance monitoring and pharmaco-epidemiological studies, to identify potential safety concerns. In addition, pharmacologists must play a major role in educating the general public about drugs, aiding in the accurate interpretation of the benefit-risk balance and preventing misinformation. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Benefit-Risk Assessment | |
| dc.subject.en | Covid | |
| dc.subject.en | Drug Adverse Reaction | |
| dc.subject.en | Drug-Drug Interaction | |
| dc.subject.en | Effectiveness | |
| dc.subject.en | Efficacy | |
| dc.subject.en | Pharmacology | |
| dc.title.en | Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic | |
| dc.title.alternative | Expert Opin Drug Saf | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1080/14740338.2024.2368811 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38898690 | en_US |
| bordeaux.journal | Expert Opinion on Drug Safety | en_US |
| bordeaux.page | 959-967 | en_US |
| bordeaux.volume | 23 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 8 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04730164 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-10-10T10:11:49Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Expert%20Opinion%20on%20Drug%20Safety&rft.date=2024-08-01&rft.volume=23&rft.issue=8&rft.spage=959-967&rft.epage=959-967&rft.eissn=1744-764X&rft.issn=1744-764X&rft.au=CRACOWSKI,%20Jean-Luc&MOLIMARD,%20Mathieu&RICHARD,%20Vincent&ROUSTIT,%20Matthieu&KHOURI,%20Charles&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||